Title |
A Pilot Study Using Next-Generation Sequencing in Advanced Cancers: Feasibility and Challenges
|
---|---|
Published in |
PLOS ONE, October 2013
|
DOI | 10.1371/journal.pone.0076438 |
Pubmed ID | |
Authors |
Glen J. Weiss, Winnie S. Liang, Michael J. Demeure, Jeff A. Kiefer, Galen Hostetter, Tyler Izatt, Shripad Sinari, Alexis Christoforides, Jessica Aldrich, Ahmet Kurdoglu, Lori Phillips, Hollie Benson, Rebecca Reiman, Angela Baker, Vickie Marsh, Daniel D. Von Hoff, John D. Carpten, David W. Craig |
Abstract |
New anticancer agents that target a single cell surface receptor, up-regulated or amplified gene product, or mutated gene, have met with some success in treating advanced cancers. However, patients' tumors still eventually progress on these therapies. If it were possible to identify a larger number of targetable vulnerabilities in an individual's tumor, multiple targets could be exploited with the use of specific therapeutic agents, thus possibly giving the patient viable therapeutic alternatives. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 10 | 59% |
Belgium | 2 | 12% |
Spain | 1 | 6% |
Australia | 1 | 6% |
Unknown | 3 | 18% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 11 | 65% |
Scientists | 5 | 29% |
Practitioners (doctors, other healthcare professionals) | 1 | 6% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 7% |
Japan | 1 | 2% |
Unknown | 40 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 23% |
Student > Doctoral Student | 6 | 14% |
Student > Bachelor | 6 | 14% |
Student > Ph. D. Student | 5 | 11% |
Professor | 2 | 5% |
Other | 7 | 16% |
Unknown | 8 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 25% |
Agricultural and Biological Sciences | 7 | 16% |
Biochemistry, Genetics and Molecular Biology | 6 | 14% |
Psychology | 3 | 7% |
Computer Science | 2 | 5% |
Other | 3 | 7% |
Unknown | 12 | 27% |